Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperamplification, which leads to aberrant mitosis and chromosome instability. Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperamplification. Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperamplification is frequent in both tumor types. Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperamplification. However, in some cases, we observed centrosome hyperamplification in tumors that retained wild-type p53. These tumors contained high levels of Mdm2. Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperamplification. We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperamplification and chromosome instability in cultured cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that Mdm2 overexpression can promote certain forms of genome instability, such as aneuploidy and centrosome duplication (9, 50).”
From Mdm2 Promotes Genetic Instability and Transformation Independent of p53 (2008) · cites this paper as [9]
In the citing paper
“higher levels are incompatible with life in vivo and in vitro, except in some cases when p53 is also inactivated”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Carroll, et al., 1999
In the citing paper
“Small increases in Mdm2 levels in normal cells are tolerated”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Carroll, et al., 1999
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 2×
“The p53 tumor suppressor gene is the most frequently mutated gene in human cancer (Hollstein et al., 1991; Levine et al., 1991).”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 2×
“…proteosome pathway *Correspondence: K Fukasawa Received 20 July 1998; revised 1 October 1998; accepted 23 October 1998 Oncogene (1999) 18, 1935 ± 1944 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $12.00 http://www.stockton-press.co.uk/onc (Haupt et al., 1997; Kubbutat et al., 1997).”
BackgroundInfluentialThe p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788 · cited 2×
“The p53 tumor suppressor gene is the most frequently mutated gene in human cancer (Hollstein et al., 1991; Levine et al., 1991).”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 4×
“…proteosome pathway *Correspondence: K Fukasawa Received 20 July 1998; revised 1 October 1998; accepted 23 October 1998 Oncogene (1999) 18, 1935 ± 1944 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $12.00 http://www.stockton-press.co.uk/onc (Haupt et al., 1997; Kubbutat et al., 1997).”
BackgroundInfluentialMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 1×
“Mdm2 binds to p53 at the Nterminal transactivating domain, and inhibits the transactivation function of p53 (Momand et al., 1992; Oliner et al., 1993; Chen et al., 1993; Picksley et al., 1994).”
BackgroundBloom, H. J. G., & Richardson, W. W. (1957) · British Journal of Cancer · doi:10.1038/bjc.1957.43 · Cited by 2,925 · cited 1×
“A total of eight breast ductal carcinomas [grade III (Bloom-Richardson grade, Bloom and Richardson, 1957), poorly di erentiated, lymph node positive], and 12 SCCHN [stage 3 and 4 (UICC), poorly to moderately di erentiated, lymph node positive] were examined.”
BackgroundGenetic instability in colorectal cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386623a0 · Cited by 1,986 · cited 1×
“Some previous studies have failed to detect a clear correlation between the p53 mutation and chromosome instability (Lengauer et al., 1997).”
BackgroundAmplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · cited 3×
“Importantly, the ampli®cation of Mdm2 occurs preferentially in tumors that do not have p53 mutations (Oliner et al., 1992).”
BackgroundMethodInfluential
Research works printed but not linked: 3
- Chen J, Marechal V and Levine A. . 1993 Mol. Cell. Biol. 13: 4107–4114. · DOI · Paper page
- Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC and Rabinovtich PS. . 1992 Gastroenterology 102: 1212–1219. · doi:10.1016/0016-5085(92)90758-q · Paper page
- Vandre DD and Borisy GG. . (1989) The centrosome cycle in animal cells. In Mitosis: Molecules and Mechanisms. Hyams JS and Brinkley BR (eds). Academic Press: San Diego pp.39–75.
Cited by
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Centrosome aberrations: cause or consequence of cancer progression?
Nigg, E. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc924 · Cited by 732
Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication
Okuda, M., Horn, H. F., Tarapore, P., Tokuyama, Y., Smulian, A. G., Chan, P.-K., Knudsen, E. S., Hofmann, I. A., Snyder, J. D., Bove, K. E., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00093-3 · Cited by 685
Self-citationMeraldi, P. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.483 · Cited by 658
Plk4-Induced Centriole Biogenesis in Human Cells
Kleylein-Sohn, J., Westendorf, J., Le Clech, M., Habedanck, R., Stierhof, Y.-D., & Nigg, E. A. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.07.002 · Cited by 659
Metadata
- Authors
- Carroll, P. E., Okuda, M., Horn, H. F., Biddinger, P., Stambrook, P. J., Gleich, L. L., Li, Y.-Q., Tarapore, P., & Fukasawa, K.
- Affiliations
- University of Cincinnati (US)
- Venue
- Oncogene
- Published
- 1999-03-18
- Volume
- 18
- Issue
- 11
- Pages
- 1935-1944
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2321611063
- Cited by
- 279
- References
- 53
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 7 · 2022: 4 · 2021: 10 · 2020: 9 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 6 · 2015: 2 · 2014: 6 · 2013: 8 · 2012: 13
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- chromosomal instability, TP53 mutation, MDM2 overexpression, breast ductal carcinoma, head and neck squamous cell carcinoma, aberrant mitosis, loss of heterozygosity, p53 inactivation, tumor suppressor loss
- MeSH terms
- Animals, Breast Neoplasms, Gene Amplification, Head and Neck Neoplasms, Humans, Nuclear Proteins, Proto-Oncogene Proteins, Gene Expression, Tumor Suppressor Protein p53, Mutagenesis, 3T3 Cells, Carcinoma, Ductal, Breast, Neoplasms, Squamous Cell, Centrosome, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. https://app.cochat.ai/papers/10.1038/sj.onc.1202515
- The paper
- Carroll, P. E., Okuda, M., Horn, H. F., Biddinger, P., Stambrook, P. J., Gleich, L. L., Li, Y.-Q., Tarapore, P., & Fukasawa, K. (1999). Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene. https://doi.org/10.1038/sj.onc.1202515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.